Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: 25th European Workshop for Rheumatology Research

Open Badges Poster presentation

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept

X Baraliakos1, J Davis2, W Tsuji3 and J Braun1

Author Affiliations

1 Rheumazentrum Ruhrgebiet, Herne, Germany

2 Division of Rheumatology, University of California, San Francisco, California, USA

3 Amgen Inc., Thousand Oaks, California, USA

For all author emails, please log on.

Arthritis Research & Therapy 2005, 7(Suppl 1):P27  doi:10.1186/ar1548

The electronic version of this article is the complete one and can be found online at:

Received:11 January 2005
Published:17 February 2005

© 2005 BioMed Central Ltd


To assess spinal inflammation by magnetic resonance imaging (MRI) before and after treatment with the tumor necrosis factor (TNF) receptor fusion protein etanercept compared with placebo.


MRI examinations of the lower thoracic and lumbar spine of 40 patients with active ankylosing spondylitis (AS) were performed as part of the recently published randomized controlled trial at four different timepoints: baseline (BL), after 12 weeks (FU1), 24 weeks (FU2) and 48 weeks (FU3). Nineteen patients received etanercept twice weekly, 2 × 25 mg subcutaneously, for 1 year and 21 patients received placebo for 6 months (until FU2) before switching to etanercept. The patients' (mean age 39.7 years, 75% male, 89% HLA-B27-positive) mean disease duration was 13 years. MRI examinations included T1-weighted sequences before (T1) and after application of gadolinium-diethylenetriamine-pentaacetic-acid (T1/Gd-DTPA) and T2-weighted fat-saturated (T2-FS) sequences. MRI examinations were scored by a modified ASspiMRI score using predefined vertebral units as a basis.


After 12 weeks, spinal inflammation (T2-FS) regressed by 54% (1.33 mean scoring points per vertebral units at BL and 0.61 at FU1, P = 0.002) in the etanercept group, but worsened by 13% in the placebo group (0.94 at BL and 1.06 at TP1, respectively; P < 0.05). After switching to etanercept, placebo patients improved similarly. T1/Gd-DTPA MRI sequences performed equally well. About 60% of all active lesions at BL were detected in the thoracic spine. There were no significant changes in the chronicity score.


Treatment with etanercept of patients with active AS results in regression of spinal inflammation as assessed by spinal MRI. Inclusion of the thoracic spine in MRI examinations of AS patients may be of particular importance.